UTHR Stock Summary and Trading Ideas (United Therapeutics | NASDAQ:UTHR)

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.

As of February 28, 2025, UTHR stock price declined to $320.05 with 605,749 million shares trading.

UTHR has a market cap of $14.37 billion. This is considered a Large Cap stock.

Last quarter United Therapeutics reported $736 million in Revenue and $6.19 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.12.

In the last 3 years, UTHR traded as high as $417.82 and as low as $158.38.

The top ETF exchange traded funds that UTHR belongs to (by Net Assets): VTI, IJH, VB, VBR, VXF.

UTHR has outperformed the market in the last year with a return of +40.8%, while the SPY ETF gained +18.8%. However, in the most recent history, UTHR shares have underperformed the stock market with its stock returning -15.4% in the last 3 month period and -13.6% for the last 2 week period, while SPY has returned -0.4% and -2.5%, respectively.

UTHR support price is $315.84 and resistance is $331.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR shares will trade within this expected range on the day.